Report Ocean has recently released its “Saudi Arabia Diabetes Drugs Market” Research Report for the years 2024-2032, presenting a comprehensive analysis of the market. This report extensively explores ...
Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).
A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor.
Sharon Mann has lost nearly 30 pounds since starting on Mounjaro, a GLP-1 medication. Dr. Sanjay Gupta reports.
The GLP-1s include semaglutide (Ozempic, Wegovy) and the combination of GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound).
As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two ...
In January 2020, spending on Ozempic, a Type 2 diabetes-indicated GLP-1, was just $4.6 million ... such as Wegovy and Zepbound. This combination of increased usage and expanded state coverage ...
In January 2020, spending on Ozempic, a Type 2 diabetes-indicated GLP-1, was just $4.6 million ... such as Wegovy and Zepbound. This combination of increased usage and expanded state coverage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback